LPL and hepatocellular carcinoma: To further validate whether ANGPTL3 is the direct downstream mediator of SREBP2 in regulating LPL activity in the absence of LDLR, CRISPR/Cas9 system was used to knock out SREBF2 and ANGPTL3 individually or together in human hepatoma Huh7 cells lacking LDLR.